Literature DB >> 14715439

Hyperactivity following postnatal NMDA antagonist treatment: reversal by D-amphetamine.

Anders Fredriksson1, Trevor Archer.   

Abstract

Three experiments were performed to study the effects of neonatal administration of glutamate receptor antagonists, on either Day 11 (dizocilpine = MK-801, 3 x 0.5 mg/kg, s.c., injected at 0800, 1600 and 2400 h) or Day 10 (Ketamine, 1 x 50 mg/kg, s.c., or Ethanol-Low, 1 x 2.5 mg/kg, or, Ethanol-High, 2 x 2.5 mg/kg, s.c., with 2-h interval) to male mice pups, on spontaneous motor behavior, habituation to a novel situation and D-amphetamine-induced activity in the adult animals. Mice administered MK-801 showed initial hypoactivity followed by hyperactivity over the later (20-40 and 40-60 min) periods of testing. Mice administered Ketamine and Ethanol-High similarly displayed an initial hypoactivity followed by hyperactivity over the later time (20-60 min) of testing. Habituation to the novel activity test chambers was reduced drastically in the MK-801 mice compared with vehicle-treated mice. Similarly, mice administered Ketamine and Ethanol-High displayed too drastically reduced habituation behavior. The low dose of D-amphetamine (0.25 mg/kg) reduced the hyperactivity of neonatal MK-801-treated mice, particularly from 30-60 min onwards, and elevated the activity level of the vehicle-treated mice. Similarly, the low dose of D-amphetamine (0.25 mg/kg) reduced the hyperactivity of neonatally Ketamine-treated and Ethanol-High-treated mice, particularly from 30-60 min onwards, and elevated the activity level of the respective vehicle-treated mice. Fluoro-jade staining per mm(2) regional brain tissue of MK-801 mice pups expressed as percent of vehicle mice pups showed also that the extensiveness of staining was markedly greater in the parietal cortex, hippocampus, frontal cortex, and lesser so in the laterodorsal thalamus. Ketamine-treated mice showed cell degeneration mainly in the parietal cortex, whereas the Ethanol-High mice showed marked cell degeneration in both the parietal and laterodorsal cortex. The present findings that encompass a pattern of regional neuronal degeneration, disruptions of spontaneous motor activity, habituation deficits and reversal of hyperactivity by a low dose of D-amphetamine suggest a model of Attention Deficit Hyperactivity Disorder that underlines the intimate role of N-methyl-D-aspartate (NMDA) receptors in the developing brain.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14715439     DOI: 10.1007/bf03033165

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  87 in total

Review 1.  Treatment of attention-deficit-hyperactivity disorder.

Authors:  J Elia; P J Ambrosini; J L Rapoport
Journal:  N Engl J Med       Date:  1999-03-11       Impact factor: 91.245

Review 2.  Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders.

Authors:  J Biederman; J Newcorn; S Sprich
Journal:  Am J Psychiatry       Date:  1991-05       Impact factor: 18.112

Review 3.  Neurotransmitters and apoptosis in the developing brain.

Authors:  C Ikonomidou; P Bittigau; C Koch; K Genz; F Hoerster; U Felderhoff-Mueser; T Tenkova; K Dikranian; J W Olney
Journal:  Biochem Pharmacol       Date:  2001-08-15       Impact factor: 5.858

4.  Cerebellum in attention-deficit hyperactivity disorder: a morphometric MRI study.

Authors:  P C Berquin; J N Giedd; L K Jacobsen; S D Hamburger; A L Krain; J L Rapoport; F X Castellanos
Journal:  Neurology       Date:  1998-04       Impact factor: 9.910

5.  Hypofrontality in attention deficit hyperactivity disorder during higher-order motor control: a study with functional MRI.

Authors:  K Rubia; S Overmeyer; E Taylor; M Brammer; S C Williams; A Simmons; E T Bullmore
Journal:  Am J Psychiatry       Date:  1999-06       Impact factor: 18.112

6.  Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex.

Authors:  B Moghaddam; B Adams; A Verma; D Daly
Journal:  J Neurosci       Date:  1997-04-15       Impact factor: 6.167

7.  Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status.

Authors:  S Mannuzza; R G Klein; A Bessler; P Malloy; M LaPadula
Journal:  Arch Gen Psychiatry       Date:  1993-07

8.  Chronic neonatal MK-801 treatment results in an impairment of spatial learning in the adult rat.

Authors:  J A Gorter; J P de Bruin
Journal:  Brain Res       Date:  1992-05-15       Impact factor: 3.252

9.  NMDA antagonist neurotoxicity: mechanism and prevention.

Authors:  J W Olney; J Labruyere; G Wang; D F Wozniak; M T Price; M A Sesma
Journal:  Science       Date:  1991-12-06       Impact factor: 47.728

Review 10.  Environmental agents that have the potential to trigger massive apoptotic neurodegeneration in the developing brain.

Authors:  J W Olney; N B Farber; D F Wozniak; V Jevtovic-Todorovic; C Ikonomidou
Journal:  Environ Health Perspect       Date:  2000-06       Impact factor: 9.031

View more
  9 in total

1.  Attention-deficit/hyperactivity disorder after early exposure to procedures requiring general anesthesia.

Authors:  Juraj Sprung; Randall P Flick; Slavica K Katusic; Robert C Colligan; William J Barbaresi; Katarina Bojanić; Tasha L Welch; Michael D Olson; Andrew C Hanson; Darrell R Schroeder; Robert T Wilder; David O Warner
Journal:  Mayo Clin Proc       Date:  2012-02       Impact factor: 7.616

2.  Neurobehavioural deficits associated with apoptotic neurodegeneration and vulnerability for ADHD.

Authors:  Anders Fredriksson; Trevor Archer
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

3.  Hyperactivity and depression-like traits in Bax KO mice.

Authors:  Thomas E Krahe; Alexandre E Medina; Crystal L Lantz; Cláudio C Filgueiras
Journal:  Brain Res       Date:  2015-09-09       Impact factor: 3.252

4.  Atypical anti-schizophrenic drugs prevent changes in cortical N-methyl-D-aspartate receptors and behavior following sub-chronic phencyclidine administration in developing rat pups.

Authors:  Noelle C Anastasio; Kenneth M Johnson
Journal:  Pharmacol Biochem Behav       Date:  2008-10       Impact factor: 3.533

5.  Long-Term Neurobehavioral Consequences of a Single Ketamine Neonatal Exposure in Rats: Effects on Cellular Viability and Glutamate Transport in Frontal Cortex and Hippocampus.

Authors:  Tuane Bazanella Sampaio; Laíse Figueiredo de Oliveira; Leandra Celso Constantino; Ana Paula Costa; Gabriela Godoy Poluceno; Wagner Carbolin Martins; Tharine Dal-Cim; Karen Andrinéia de Oliveira; Fabiana Kalyne Ludka; Rui Daniel Prediger; Carla Inês Tasca; Frederico C Pereira
Journal:  Neurotox Res       Date:  2018-07-02       Impact factor: 3.911

6.  Serotoninergics attenuate hyperlocomotor activity in rats. Potential new therapeutic strategy for hyperactivity.

Authors:  Ryszard Brus; Przemyslaw Nowak; Ryszard Szkilnik; Urszula Mikolajun; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

7.  Action sequencing in the spontaneous swimming behavior of zebrafish larvae - implications for drug development.

Authors:  Tobias Palmér; Fredrik Ek; Olof Enqvist; Roger Olsson; Kalle Åström; Per Petersson
Journal:  Sci Rep       Date:  2017-06-09       Impact factor: 4.379

8.  Combined Treatment with Low-Dose Ionizing Radiation and Ketamine Induces Adverse Changes in CA1 Neuronal Structure in Male Murine Hippocampi.

Authors:  Daniela Hladik; Sonja Buratovic; Christine Von Toerne; Omid Azimzadeh; Prabal Subedi; Jos Philipp; Stefanie Winkler; Annette Feuchtinger; Elenore Samson; Stefanie M Hauck; Bo Stenerlöw; Per Eriksson; Michael J Atkinson; Soile Tapio
Journal:  Int J Mol Sci       Date:  2019-12-03       Impact factor: 5.923

Review 9.  Novel mechanisms and approaches in the study of neurodegeneration and neuroprotection. a review.

Authors:  Richard M Kostrzewa; Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.978

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.